AMD3100 has been submitted to clinical trials for evaluation of its safety and efficacy in various cancer patients (clinical trial ID: NCT0128857, NCT02221479, NCT01696461, etc.), and is considered more suitable for clinical application as an anti-CIPN medicine than peptidic CXCR4 antagonists, such as BL-8040 (T140), LY2510924, and POL6326 (balixafortide). This evidence concerns the gene CXCR4 and cancer.